Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 safety, pharmacokinetics, food-effect, and drug-drug interaction study of APX001 in healthy volunteers
NL-OMON45345Phase 1Active, not recruiting
- Sponsor
- Amplyx Pharmaceuticals
- Start
- Oct 2016
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of fosmanogepix in mycoses (4 arms), sponsored by Amplyx Pharmaceuticals. Primary endpoint: Safety and tolerability. Started Oct 2016; status: active, not recruiting.
02
Drugs
fosmanogepix
03
Conditions
mycoses
Beyond the preview
Go deeper on NL-OMON45345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45345.